Table 1. Patient characteristics.
| Number of patients | All | IgG patients | IgA patients |
|---|---|---|---|
| 156 | 100 | 56 | |
| Age (years), median (range) | 66 (32–94) | 66 (37–86) | 66 (32–94) |
| Sex (male/female) | 82/74 | 51/49 | 31/25 |
| β2 microglobulin (median, range (mg/l)) | 3.7 | 3.7 | 3.9 |
| Albumin (median, range (g/dl)) | 3.8 (1.6–5.1) | 3.8 | 3.8 |
| FLC ratio | 24.8 (0.7–41.100) | 26.1 (0.7–41.100) | 18.1 (0.88–10100) |
| HLC ratio | 38.4 | 29.4 | 85.3 |
| IgG (g/l) | 15.0 (0.9–112.0) | 36.2 (3.2–112.0) | 4.8 (0.9–15.6) |
| IgA (g/l) | 0.72 (0.1–117.2) | 0.3 (0.1–4.7) | 27.1 (2.8–117.2) |
| IgM (g/l) | 0.14 (0.01–2.98) | 0.16 (0.01–2.98) | 0.10 (0.01–1.24) |
| M protein migration in β region | 31 | 4 | 27 |
| ISS stage I | 59 | 39 | 20 |
| ISS stage II | 63 | 35 | 28 |
| ISS stage III | 34 | 26 | 8 |
| IgGκ/IgGλ–IgAκ/IgAλ | 64/36–33/23 | 64/36 | 33/23 |
| Median follow-up (months; range) | 46.1 (0.5–157.8) | 56.2 (0.5–157.8) | 25.3 (0.5–125.9) |
| Median overall survival (months 95% CI) | 53.5 (47.3–59.6) | 61.8 (54.1–69.6) | 38.5 (29.4–47.5) |
Abbreviations: FLC, free light chain test; HLC, heavy/light chain; ISS, International Staging System.